Clinical Trials Logo

All-cause Mortality clinical trials

View clinical trials related to All-cause Mortality.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05814172 Recruiting - All-cause Mortality Clinical Trials

ADL and CONUT for Predicting 1-year Mortality Risk in Older Adults After Hip Fracture

Start date: October 2023
Phase:
Study type: Observational

Hip fracture has a serious impact on the quality of life and even the survival of older adults. The multidisciplinary management of hip fracture has been shown to be effective in improving patient outcome and cost-effective in international studies. As geriatricians and members of a multi-disciplinary team(MDT), we are aware of various scores in predicting the 1-year mortality risk in hospitalized older adults with multimorbidity. However, given the need for a deeper understanding of the preoperative status of elderly patients who were suffering from pain, tension, anxiety, delirium,etc., we hope to explore a simple, quick, objective, and accurate method for assessing the status of elderly patients with hip fractures to predict their survival risk.

NCT ID: NCT03206593 Recruiting - Clinical trials for Ischemic Heart Failure

Serum Lipids and Glucose Levels in Relation to CVD Outcomes in Patients With Ischemic Heart Failure

Start date: January 1, 2016
Phase: N/A
Study type: Observational [Patient Registry]

Current prospective cohort study is to evaluate the association between fasting lipid profiles (including total cholesterol, low density lipoprotein-cholesterol, high density lipoprotein-cholesterol, triglycerides, apolipoprotein A, apolipoprotein B and lipoprotein(a)) and fasting plasma glucose at admission with cardiovascular disease outcomes (including fatal and non-fatal myocardial infarction, fatal and non-fatal ischemic stroke, re-hospitalization due to heart failure, revascularization by percutaneous coronary intervention or coronary artery bypass grafting, or cardiovascular mortality) and all-cause mortality.in patients with ischemic heart failure and left ventricular ejection fraction < 45 % evaluated by echocardiography during 12 months follow-up.